Burkitt lymphoma in a child with osteogenesis imperfecta by Choi, Sung W. & Wechsler, Daniel S.
Pediatr Blood Cancer 2005;45:863–864
LETTER TO THE EDITOR
Burkitt Lymphoma in a Child With Osteogenesis Imperfecta
To theEditor:We readwith interest the report ofBurkitt
lymphoma in a child with Joubert syndrome [1], which
highlights the observation that patients with congenital
malformations may be at increased risk of developing
malignances [2,3]. We recently cared for a 5-year-old boy
with osteogenesis imperfecta who also developed a
Burkitt lymphoma. The family history was significant
for a father and two older siblings with a known diagnosis
of osteogenesis imperfecta type I. The patient had sus-
tained only one fracture at age 3, involving the left radius
and ulna. He presented with progressive abdominal
distention, tachypnea, and shortness of breath. Chest X-
ray showed bilateral pleural effusions, and a computed
tomography scan revealed soft tissue masses at the right
cardiophrenic angle and at the right postero-lateral aspect
of the thoraco-abdominal junction. There was a large
amount of ascites throughout the abdomen with thickened
areas of peritoneum and confluent lymph node enlarge-
ment. Malignant fluid removed from a thoracentesis and
paracentesis revealed a clonal B cell population expres-
sing CD10 (dim), CD19, CD20, FMC7, and lambda light
chains, consistent with aggressive B cell lymphoma.
Histologically, the fluid sample revealed markedly atypi-
cal cells with prominent nucleoli and darkly basophilic
cytoplasm with very prominent cytoplasmic vacuoliza-
tion. Cytogenetic analysis revealed a t(8;14) translocation.
There was no bone marrow or central nervous system
involvement.
The patient was diagnosed with stage III Burkitt lym-
phoma and was treated according to Children’s Cancer
Group protocol no. 5961, regimen B1. Induction che-
motherapy was complicated by profound abdominal
ascites and mild respiratory compromise which required
several thoracenteses and paracenteses. He tolerated the
remainder of his 4 months chemotherapy course without
problems. He remains in clinical remission 2 years fol-
lowing diagnosis. Since the diagnosis of Burkitt lym-
phoma, he has sustained several additional fractures
secondary to trauma: bilateral mandible fractures, T5
and L2 compression fractures, and a T9 burst fracture.
Osteogenesis imperfecta is a rare congenital connective
tissue disorder with considerable phenotypic variability.
Prognosis ultimately depends on the degree of severity.
The incidence of fractures varies widelywith age [4], level
of activity, and success of surgical interventions [5]. There
is no known increased risk for developing a malignancy in
children with osteogenesis imperfecta. Rare pediatric
patients with osteogenesis imperfecta have developed
osteosarcoma [6] or familial leukemia [7]. There have also
been case reports of adults with osteogenesis imperfecta
who have developed osteosarcoma [8], breast carcinoma
[9], ovarian serous carcinoma [10], andmultiple myeloma
[11].
Osteogenesis imperfecta is associated with deletion of
ormutation in the collagen type I, alpha-1 or alpha-2 genes
(COL1A1 or COL1A2) [12,13], located at chromosomes
17q21.31-q22 and 7q22.1, respectively. Burkitt lym-
phoma results from chromosome translocations that
involve the c-MYC oncogene (chromosome 8q24) and
regulatory regions of immunoglobulin (Ig) heavy chains
(14q32), kappa (2p12), or lambda light chains (22q11)
[14], resulting in t(8;14), t(8;2), and t(8;22). Since there
have not been anyprevious reports of Burkitt lymphoma in
osteogenesis imperfecta patients, it is likely that this asso-
ciation is a randomoccurrence. However, since collagen is
a key component of the hematopoietic microenvironment,
it is possible that alteration of the extracellular matrix
could have perturbed hematopoiesis and contributed to
malignant transformation. From a clinical perspective, our
patient’s underlying condition did not affect his ability to
tolerate and respond to chemotherapy. Should future cases
arise, this knowledge may be of interest.
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